CN1820018B - 由蛇毒腺分泌的肽的药物组合物制剂 - Google Patents
由蛇毒腺分泌的肽的药物组合物制剂 Download PDFInfo
- Publication number
- CN1820018B CN1820018B CN2003801081877A CN200380108187A CN1820018B CN 1820018 B CN1820018 B CN 1820018B CN 2003801081877 A CN2003801081877 A CN 2003801081877A CN 200380108187 A CN200380108187 A CN 200380108187A CN 1820018 B CN1820018 B CN 1820018B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- composition according
- peptide
- evasin
- evasins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Nanotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medical Informatics (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0205449-3 | 2002-12-09 | ||
| BRPI02054493 | 2002-12-09 | ||
| BRPI0205449-3A BR0205449A (pt) | 2002-12-09 | 2002-12-09 | composições farmacêuticas de peptìdeos, secretados pelas glándulas do veneno de serpentes, particurlamente da bothrops jararaca, inibidores de vasopeptidases, evasins, seus análogos, derivaados e produtos associados para o desenvolvimento de aplicações e uso em doenças crÈnico-degenerativas |
| PCT/BR2003/000192 WO2004052273A2 (en) | 2002-12-09 | 2003-12-09 | Pharmaceutical compositions preparation of peptides, secreted by the snake venom glands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1820018A CN1820018A (zh) | 2006-08-16 |
| CN1820018B true CN1820018B (zh) | 2011-11-16 |
Family
ID=32476825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2003801081877A Expired - Fee Related CN1820018B (zh) | 2002-12-09 | 2003-12-09 | 由蛇毒腺分泌的肽的药物组合物制剂 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080199503A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1581550A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006517520A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1820018B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003302871A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0205449A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2507980A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05006170A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004052273A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010538991A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としてのsfllr−ohおよびムラミルジペプチドの使用 |
| US9993793B2 (en) | 2010-04-28 | 2018-06-12 | The Procter & Gamble Company | Delivery particles |
| US9186642B2 (en) | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
| US8980292B2 (en) | 2011-04-07 | 2015-03-17 | The Procter & Gamble Company | Conditioner compositions with increased deposition of polyacrylate microcapsules |
| WO2012138710A2 (en) | 2011-04-07 | 2012-10-11 | The Procter & Gamble Company | Personal cleansing compositions with increased deposition of polyacrylate microcapsules |
| US8927026B2 (en) | 2011-04-07 | 2015-01-06 | The Procter & Gamble Company | Shampoo compositions with increased deposition of polyacrylate microcapsules |
| US12486478B2 (en) | 2020-10-16 | 2025-12-02 | The Procter & Gamble Company | Consumer products comprising delivery particles with high core:wall ratios |
| EP4229164A1 (en) | 2020-10-16 | 2023-08-23 | The Procter & Gamble Company | Consumer product compositions with at least two encapsulate populations |
| JP7719177B2 (ja) | 2020-10-16 | 2025-08-05 | ザ プロクター アンド ギャンブル カンパニー | 封入体の集団を含む消費者製品組成物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440749A1 (en) * | 2001-03-19 | 2002-09-26 | Biolab Sanus Farmaceutica Ltda. | Isolation and purification procedure of vasopeptidase peptide inhibitors |
-
2002
- 2002-12-09 BR BRPI0205449-3A patent/BR0205449A/pt not_active IP Right Cessation
-
2003
- 2003-12-09 EP EP03812538A patent/EP1581550A2/en not_active Withdrawn
- 2003-12-09 WO PCT/BR2003/000192 patent/WO2004052273A2/en not_active Ceased
- 2003-12-09 CN CN2003801081877A patent/CN1820018B/zh not_active Expired - Fee Related
- 2003-12-09 US US10/537,264 patent/US20080199503A1/en not_active Abandoned
- 2003-12-09 MX MXPA05006170A patent/MXPA05006170A/es unknown
- 2003-12-09 JP JP2004557689A patent/JP2006517520A/ja active Pending
- 2003-12-09 CA CA002507980A patent/CA2507980A1/en not_active Abandoned
- 2003-12-09 AU AU2003302871A patent/AU2003302871A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440749A1 (en) * | 2001-03-19 | 2002-09-26 | Biolab Sanus Farmaceutica Ltda. | Isolation and purification procedure of vasopeptidase peptide inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006517520A (ja) | 2006-07-27 |
| AU2003302871A1 (en) | 2004-06-30 |
| AU2003302871A8 (en) | 2004-06-30 |
| WO2004052273A2 (en) | 2004-06-24 |
| CA2507980A1 (en) | 2004-06-24 |
| EP1581550A2 (en) | 2005-10-05 |
| WO2004052273A3 (en) | 2005-04-21 |
| US20080199503A1 (en) | 2008-08-21 |
| BR0205449A (pt) | 2006-03-07 |
| CN1820018A (zh) | 2006-08-16 |
| MXPA05006170A (es) | 2005-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100525830C (zh) | 采用环糊精、脂质体和生物降解性聚合物和/或其混合物及其制品制备肽血管紧张素-(1-7)和类似物、激动剂和拮抗剂制剂的方法 | |
| EP3185880B1 (en) | Improved peptidyl calcineurin inhibitors | |
| CN102124023A (zh) | 用于疾病治疗的肽Des-[ASP1]-[ALA1],血管紧张素-(1-7)激动剂和药物组合物 | |
| KR101958964B1 (ko) | 항종양 및 항혈관생성 활성을 갖는 사이클릭 펩타이드 | |
| Wang et al. | Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity | |
| US20080199503A1 (en) | Pharmaceutical Compositions Preparation of Peptides, Secreted by the Snake Venom Glands, Particularly of Bothrops Jararaca, Vasopeptidases Inhibitors, Evasins, Their Analogues, Derivatives and Products Associated, Thereof, for Development of Applications and Use in Chronic-Degenerative Diseases | |
| EP1685153A1 (en) | Targeting compositions and preparation thereof | |
| WO2014059385A1 (en) | Methods and small molecule therapeutics comprising fused elps | |
| US8653031B2 (en) | Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7) | |
| CA2107773A1 (en) | Hepatoma treatment with somatostatin analogs | |
| US6083915A (en) | Method for treating liver cancer | |
| KR102017973B1 (ko) | 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제 | |
| EP4578867A1 (en) | Cyclic peptide or salt thereof and mdmx inhibitor | |
| CN107586316B (zh) | 具有血栓溶解活性的多肽 | |
| US20250177479A1 (en) | Depsipeptide-based amphiphilic buliding block to inhibit protein-protein interactions, nanostructure comprised thereof and uses thereof | |
| BRPI0504978B1 (pt) | Processo de preparação de compostos entre os antagonistas do receptor at1 e angiotensina-(1-7) seus análogos e/ou misturas desses sistemas, suas composições farmacêuticas e uso dos produtos derivados | |
| HK1015123B (en) | Hepatoma treatment with somatostatin analogs | |
| HK1006947B (en) | Treatment of liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 Termination date: 20111209 |